PT - JOURNAL ARTICLE AU - Karakike, Eleni AU - Dalekos, George N. AU - Koutsodimitropoulos, Ioannis AU - Saridaki, Maria AU - Pourzitaki, Chryssa AU - Papathanakos, Georgios AU - Kotsaki, Antigone AU - Chalvatzis, Stamatios AU - Dimakopoulou, Vasiliki AU - Vechlidis, Nikolaos AU - Paramythiotou, Elisabeth AU - Avgoustou, Christina AU - Ioakeimidou, Aikaterini AU - Kouriannidi, Elli AU - Komnos, Apostolos AU - Neou, Evangelia AU - Rovina, Nikoletta AU - Stefanatou, Eleni AU - Milionis, Haralampos AU - Nikolaidis, George AU - Koutsoukou, Antonia AU - Damoraki, Georgia AU - Dimopoulos, George AU - Zoumpos, Vassileios AU - Eugen-Olsen, Jesper AU - Akinosoglou, Karolina AU - Gatselis, Nikolaos K. AU - Koulouras, Vasilios AU - Gkeka, Eleni AU - Markou, Nikolaos AU - Netea, Mihai G. AU - Giamarellos-Bourboulis, Evangelos J. TI - ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients AID - 10.1101/2021.01.20.21250182 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.20.21250182 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.20.21250182.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.20.21250182.full AB - Rationale Macrophage activation syndrome (MAS) and complex immune dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19.Objective To investigate the outcome of personalized immunotherapy in critical COVID-19.Methods In this open-label prospective trial, 102 patients with SOFA (sequential organ failure assessment) score ≥2 or ARDS by SARS-CoV-2 were screened for MAS (ferritin more than 4420 ng/ml) and CID (ferritin ≤4420 ng/ml and low expression of HLA-DR on CD14-monocytes). Patients with MAS and CID with increased aminotransferases were assigned to intravenous anakinra; those with CID and normal aminotransferases to tocilizumab. The primary outcome was at least 25% decrease of SOFA score and/or 50% increase of respiratory ratio by day 8; 28-day mortality, change of SOFA score by day 28; serum biomarkers and cytokine production by mononuclear cells were secondary endpoints.Measurements and Main Results The primary study endpoint was met in 58.3% of anakinra-treated patients and in 33.3% of tocilizumab-treated patients (odds ratio 3.11; 95% CIs 1.29-7.73; P: 0.011). No differences were found in mortality and in SOFA score changes. By day 4, ferritin was decreased among anakinra-treated patients; interleukin (IL)-6, soluble urokinase plasminogen activator receptor (suPAR) and the expression of HLA-DR were increased among tocilizumab-treated patients. Anakinra increased capacity of mononuclear cells to produce IL-6. Survivors by day 28 who received anakinra were distributed to scales of the WHO clinical progression of lower severity. Greater incidence of secondary infections was found with tocilizumab treatment.Conclusions Biomarkers may guide favourable anakinra responses in critically ill patients with COVID-19.Trial Registration ClinicalTrials.gov, NCT04339712Competing Interest StatementGeorge N. Dalekos has acted as Advisor/Lecturer for Abbvie, Bristol-Myers Squibb, Gilead, Novartis, Roche, Amgen, MSD, Janssen, Ipsen, Genkyotex, Sobi and Pfizer, has received Grant support from Bristol-Myers Squib, Gilead, Roche, Janssen, Abbvie and Bayer and was or is currently PI in National & International Protocols sponsored by Abbvie, Bristol-Myers Squibb, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Bayer, Astellas, Ipsen, Pfizer, Amyndas Pharamaceuticals, CymaBay Therapeutics Inc. and Roche. E. Karakike has received funding from Horizon 2020 Marie Sklodowska-Curie Grant European Sepsis Academy (grant 676129), outside the submitted work. Haralampos Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. J. Eugen-Olsen is a cofounder, shareholder and CSO of ViroGates A7S, Denmark and is named inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. He is granted by the Horizon 2020 European Grant RISKinCOVID. M.G. Netea is a scientific founder of TTxD, and received research grants from GSK and ViiV Healthcare. E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, Angelini Italy, InflaRx GmbH, MSD Greece, XBiotech Inc., and BRAHMS GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas Pharma Europe, AxisShield, bioM&eacuterieux Inc, Novartis, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis) and the Horizon 2020 RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not report any conflict of interest.Clinical TrialNCT04339712Funding StatementThe study was funded in part by the Hellenic Institute for the Study of Sepsis and in part by the Horizon 2020 grant RISKinCOVID.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ESCAPE was an open-label phase II prospective clinical trial conducted in four departments of Internal Medicine and seven Intensive Care Units (ICUs) of tertiary hospitals in Greece between April and November 2020 (EudraCT number 2020-001039-29; Clinicaltrials.gov NCT04339712; approval 30/20 by the National Ethics Committee of Greece; approval IS 021-20 by the National Organization for Medicines of Greece).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data can be made to the corresponding author with specific data needs, analysis plans and dissemination plans.